PPD nabs Bioclinica clinical research site business

The CRO said this will boost its geogrpahic reach (PPD)

As part of its ambition to become the world’s largest patient access and site conduct organization, CRO PPD has snapped up Bioclinica’s research site biz.

This will be enveloped into PPD’s Accelerated Enrollment Solutions (AES), one of its business units, boosting the company's global footprint as it reaches into new areas including China, Latin America and western Europe.

The deal also includes those research sites from the merger of Bioclinica and CCBR-SYNARC back in 2014, bolsters the AES unit's presence in the U.S. and and adds four dedicated sites in Florida, the CRO said in a statement.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“With these new assets operating on five continents, AES is a place where customers can receive 50-100% of their entire trial enrollment from one accountable solution, delivered by research locations that operate uniformly across the globe,” said Roger Smith, senior vice president and general manager of AES.

“We can now address two major impediments to meaningful improvement in site selection and patient enrollmen—namely, investigator site capacity and the ability to predictably bring new patients into research with our data modeling and analytical capabilities.

“Our approach can reduce customers’ reliance on patient availability from investigator databases and practices. As we focus on delivering this value for our customers, we are pleased to welcome our new colleagues to AES to be part of our solution-oriented culture and help advance drug development to improve patients’ lives.”

This comes several weeks after PPD penned a collaboration with Harbour BioMed to help develop new meds for cancer and immunology.

RELATED: Bioclinica wants to move the needle in NASH

David Herron, president and CEO of Bioclinica, added: “We believe PPD’s AES business unit is an outstanding strategic fit for the global site business. Both organizations have long been committed to clinical research and together they will provide excellent value for sponsors and CROs.

“This transaction enables AES to take patient access and site conduct to a new level, while enabling Bioclinica to accelerate its delivery of exceptional services in medical imaging, cardiovascular safety, eClinical and trial software, and drug safety solutions.”

As is becoming increasingly common in the biopharma service world, financial details of the deal were not disclosed.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any safety alarms.